Literature DB >> 21634011

Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1.

Estelle Genoux-Bastide1, Doriane Lorendeau, Edwige Nicolle, Samir Yahiaoui, Sandrine Magnard, Attilio Di Pietro, Hélène Baubichon-Cortay, Ahcène Boumendjel.   

Abstract

Multidrug-resistance protein 1 (MRP1) belongs to the ATP-binding cassette (ABC) transporter family. MRP1 mediates MDR (multidrug resistance) by causing drug efflux either by conjugation to glutathione (GSH) or by co-transport with free GSH (without covalent bonding between the drug and GSH). We recently reported that the calcium channel blocker verapamil can activate massive GSH efflux in MRP1-overexpressing cells, leading to cell death through apoptosis. However, clinical use of verapamil is hampered by its cardiotoxicity. Then, in the search for compounds that act similarly to verapamil, but without major side effects, we investigated xanthones. Herein we show that xanthones induce apoptosis among resistant cells overexpressing MRP1 similarly to the verapamil effect. Among the xanthones studied, 1,3-dihydroxy-6-methoxyxanthone was identified as the most active derivative, able to specifically kill cells transfected with human MRP1 with even greater potency than verapamil. Under the same conditions, the active xanthones have no toxic effect on control (sensitive) cells. Xanthones could therefore be considered as new potential anticancer agents for the selective treatment of MRP1-positive tumors.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21634011     DOI: 10.1002/cmdc.201100102

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

2.  Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Authors:  Nathalia Daflon-Yunes; Flavio Eduardo Pinto-Silva; Raphael Silveira Vidal; Bruna Fortunato Novis; Tandressa Berguetti; Raphael Rodrigues Soares Lopes; Carla Polycarpo; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

3.  ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.

Authors:  Charlotte Gauthier; Csilla Ozvegy-Laczka; Gergely Szakacs; Balazs Sarkadi; Attilio Di Pietro
Journal:  Front Pharmacol       Date:  2013-11-07       Impact factor: 5.810

Review 4.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

5.  Regulation of MAPKs Signaling Contributes to the Growth Inhibition of 1,7-Dihydroxy-3,4-dimethoxyxanthone on Multidrug Resistance A549/Taxol Cells.

Authors:  Jian Zuo; Hui Jiang; Yan-Hong Zhu; Ya-Qin Wang; Wen Zhang; Jia-Jie Luan
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-15       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.